Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
This study is ongoing, but not recruiting participants.
Study NCT01467479   Information provided by Vertex Pharmaceuticals Incorporated

First Received on November 3, 2011.   Last Updated on October 19, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Hepatitis
Hepatitis A
HIV Infections
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Liver Diseases
Picornaviridae Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Telaprevir
Ribavirin
peginterferon alfa-2a
Additional drug interventions recognized in this trial
Interferon-alpha
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Vertex Pharmaceuticals Incorporated


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services